Excessive extracellular matrix deposition progressively replacing muscle fibres is the endpoint of most severe muscle diseases. Recent data indicate major involvement of microRNAs in regulating pro-and anti-fibrotic genes. To investigate the roles of miR-21 and miR-29 in muscle fibrosis in Duchenne muscle dystrophy, we evaluated their expression in muscle biopsies from 14 patients, and in muscle-derived fibroblasts and myoblasts. In Duchenne muscle biopsies, miR-21 expression was significantly increased, and correlated directly with COL1A1 and COL6A1 transcript levels. MiR-21 expression was also significantly increased in Duchenne fibroblasts, more so after TGF-β1 treatment. In Duchenne fibroblasts the expression of miR-21 target transcripts PTEN (phosphatase and tensin homolog deleted on chromosome 10) and SPRY-1 (Sprouty homolog 1) was significantly reduced; while collagen I and VI transcript levels and soluble collagen production were significantly increased. MiR-29a and miR-29c were significantly reduced in Duchenne muscle and myoblasts, and miR-29 target transcripts, COL3A1, FBN1 and YY1, significantly increased. MiR-21 silencing in mdx mice reduced fibrosis in the diaphragm muscle and in both Duchenne fibroblasts and mdx mice restored PTEN and SPRY-1 expression, and significantly reduced collagen I and VI expression; while miR-29 mimicking in Duchenne myoblasts significantly decreased miR-29 target transcripts. These findings indicate that miR-21 and miR-29 play opposing roles in Duchenne muscle fibrosis and suggest that pharmacological modulation of their expression has therapeutic potential for reducing fibrosis in this condition.
Introduction
In severe muscular dystrophies such as congenital muscular dystrophies and Duchenne muscular dystrophy (DMD), the primary defect leads to continuous myofibre injury and degeneration. In DMD, chronic muscle tissue damage and inflammatory infiltrates persist, resident satellite cells are unable to keep pace with the requirement for new fibres, and fibrogenic cells are continuously activated, eventually leading to massive connective tissue deposition (fibrosis) [41] . In addition to impeding fibre regeneration, fibrosis may obstruct the targeting of specific therapies (drugs or cells) to muscle, and worsen disease progression by obstructing nutrient delivery.
Fibrosis is not a peculiarity of DMD and chronic myopathies, but characterizes diseases of various tissues, including lung [40] , liver [20] , kidney [39] , heart [22] , skin [42] , and bladder [11] .
Fibroblasts play a major role in fibrosis. Normally they are involved in the repair response to injury by secreting proteins of the extracellular matrix (ECM) and growth factors, and by differentiating into contractile and secretory myofibroblasts, characterized by α-smooth muscle actin (α-SMA) expression and active ECM synthesis [29] . The cytokine TGF-β1 is also a major player in fibrosis and in particular induces differentiation of fibroblasts to myofibroblasts [10] . In fibrotic conditions in general, myofibroblasts remain at injury sites where they secrete ECM proteins in excess to thereby severely impair tissue function.
Our previous study showed that primary fibroblasts derived from DMD muscles have a pro-fibrotic phenotype probably due to intrinsic memory of their native environment, which is altered by the primary genetic defect [54, 55] . We have also shown that transcript expression and protein modulation of several ECM components are altered in DMD myotubes [58] . These findings indicate that both myogenic cells and resident fibroblasts contribute to fibrosis in DMD skeletal muscle, and to elucidate the molecular mechanisms of the fibrotic process it is essential to better understand the roles played by fibroblast and myoblast cell lineages.
MicroRNAs (miRNAs) are small non-coding RNA molecules found in plants and animals, whose main function seems to be to downregulate gene expression by various mechanisms, including, translation repression, and mRNA cleavage and deadenylation. Recent evidence indicates that miRNAs also play fundamental roles in other biological and also pathological processes. In particular, aberrant expression of miRNAs has been related to the development of fibrosis in various tissues through regulation of anti-and pro-fibrotic genes [5] .
MiR-21 was originally considered an oncomiR, as it is over-expressed in most cancer types [27] , but recent data show that it is one of the most highly upregulated miRNAs during tissue injury, and that its persistent overexpression disrupts tissue repair and contributes to tissue fibrosis in heart [6] , kidney [12] , liver [32] and lung [23] . MiR-21 is also upregulated during the wound contraction and collagen deposition phases of skin wound healing [48] , and promotes keratinocyte migration by inhibiting TIMP-3 [52] . MiR-21 is rapidly induced by TGF-β1 treatment, suggesting that it may be involved in the pro-fibrotic effects of TGF-β1 [5] . Finally, in mice with experimentally-induced or age-associated (mdx) muscle fibrosis, miR-21 biogenesis is regulated by the extracellular PAI-1/ plasmin system [3] .
Recent studies have also shown that the miR-29 family of miRNAs is involved in heart, liver, lung, and skin fibrosis [9, 16, 37, 44] . MiR-29 downregulates the expression of ECM components collagens, fibrillins and elastin, while its downregulation in the dystrophic muscles of mdx mice not only results in impaired regeneration, but also directly contributes to muscle fibrosis [47] . MiR-29 also inhibits TGF-β1 induced-transdifferentiation of myoblasts into myofibroblasts [59] . These findings suggest that miR-29 miRNAs have an anti-fibrotic role.
In view of the emerging roles of miR-21 and miR-29 in fibrotic disorders, we evaluated their expression in DMD and control muscle biopsies. We also analysed miR-21 expression in DMD and control muscle-derived fibroblast cultures (since preliminary studies, not presented, indicated that miR-21 is predominantly expressed in this cell lineage) and miR-29 expression in myoblast cultures (since our preliminary data indicate that miR-29 is predominantly expressed in these cells). We assessed the expression of these miRNAs in cultures treated and not treated with TGF-β1.
To further probe the roles of miR-21 and miR-29 in muscle fibrosis, we investigated expression levels of miR-21 and miR-29 targets before and after cell transfection with miR-21 inhibitor in DMD fibroblasts, and miR-29 mimics in DMD myoblasts, respectively.
We also examined the PAI-1/plasmin system in fibroblasts since we have previously shown that muscle-derived fibroblasts from DMD patients are fibrogenic [54, 55] and the system is involved in ECM remodelling and regulation of miR-21 biogenesis [3] . Finally, to assess the therapeutic potential of miR-21 inhibition, we treated mdx mice with antagomiR-21.
Materials and methods

Muscle biopsies and cell cultures
Quadriceps muscle biopsies were obtained after informed parental consent from 14 DMD patients (age 1-8 years; no one has ever been under steroid treatment), 5 patients with congenital muscular dystrophy 1A (MDC1A) as positive controls (age 1 month-3 years) and 11 age-matched controls (age 1-7 years) with suspected neuromuscular disease, but normal muscle on biopsy. Investigations on human tissue were approved by our institutional review board and were in accordance with the Italian law. DMD and MDC1A were diagnosed by dystrophin/laminin alpha2 chain testing and gene analysis.
Fibroblasts and myoblasts were obtained from three DMD patients (aged 2-6 years) and three age-matched controls (age 3-4 years), by immunomagnetic selection from primary muscle biopsy-derived cell cultures, as described elsewhere [58] . Fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM; Lonza Group Ltd, Basel, Switzerland), supplemented with 10% heat-inactivated foetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 1% penicillinstreptomycin (Lonza), and 2 mM L-glutamine (Lonza).
Myoblasts were cultured in DMEM supplemented with 20% FBS, 1% penicillin-streptomycin, 2 mM L-glutamine, 10 μg/ml insulin (Sigma Aldrich, St. Louis, MO, USA), 2.5 ng/ml basic fibroblast growth factor (bFGF; Gibco), and 10 ng/ml epidermal growth factor (EGF; Gibco). Experiments were performed on early passages (3-10 passages) of normal and dystrophic fibroblasts and myoblasts.
Control and DMD fibroblasts and myoblasts were treated with 10 ng/ml h-recombinant TGF-β1 (Peprotech EC, London, UK) for 48 h, as described previously [55] .
Purification and quantification of miRNA
The miRNA fraction was isolated using a miRNA isolation kit (mirVana, Ambion, Austin, TX, USA) according to the manufacturer's instructions. MiRNA was reverse-transcribed with the TaqMan miRNA Reverse Transcription kit (Life Technologies) according to the manufacturer's instructions.
MiR-21 (hsa-miR-21-3p), miR-29a (hsa-miR-29a-3p) and miR-29c (hsa-miR-29c-3p) expression levels were quantified using the TaqMan assay for miRNA and the TaqMan Universal Master Mix (both from Applied Biosystems, Carlsbad, CA, USA). MiR-U6B was used as endogenous control for miR-21, miR-29a and miR-29c.
The expression of each miRNA in control and DMD fibroblasts, myoblasts and muscle was normalized to the expression of miR-U6B and determined as the ratio of the target miRNA to the miR-U6B calculated by 2 −ΔΔCt , where ΔΔCt = Ct Target − Ct U6B . Quantitative PCR data were expressed as "fold changes" relative to control levels expressed as 1.
Each analysis was performed in duplicate and repeated at least three times with RNA from three different control and three different DMD cell lines.
Real time PCR
Total RNA was isolated from fibroblasts, myoblasts and muscle tissues using TRI Reagent (Ambion) according to the manufacturer's instructions, and checked spectrophotometrically for quantity and purity using a Nanodrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA). RNA aliquots (1 μg) were reverse-transcribed in the presence of 5× first strand buffer (Life Technologies), 1 mM each deoxynucleoside triphosphate, 8 pM random hexamers, 10 μM dithiothreitol, 1 IU/μl RNAse inhibitor (Roche Molecular Biochemicals, Basel, Switzerland), and 10 IU/μl M-MLV reverse transcriptase (Life Technologies) with incubation at 37°C for 1 h and at 95°C for 5 min. The reaction product was stored at −20°C pending use. cDNA integrity was assessed by PCR amplification of human glyceraldehyde-3-phosphate dehydrogenase (NM_ 002046.5) with specific primers (forward 5′-GAAGGTGAAGGTCGGA GTC-3′ and reverse 5′-GAAGATGGTGATGGGATTTC-3′). PCR conditions were: 94°C for 1 min, 54°C for 1 min, and 72°C for 1 min, for 35 cycles. Mouse cDNA integrity was assessed by PCR amplification of mouse actin (NM_009606.3) with specific primers (forward 5′-AGCCAT GTACGTAGCCATCC-3′ and reverse 5′-CTCTCAGCTGTGGTGGTGAA-3′).
Human COL1A1 (Hs01076772_gH), COL3A1 (Hs00943809_m1), COL6A1 (Hs01095579_g1), PTEN (Hs02621230_s1), SPRY-1 (Hs01083036_s1), FBN1 (Hs00171191_m1), YY1 (Hs00231533_ m1), PAI-1 (Hs01126604_m1, SERPINE), HMGA2 (Hs00971725_ m1), and TWF1 (Hs00702289_s1) transcripts; and mouse PTEN (Mm00477208_m1), SPRY-1 (Mm01285700_m1) and ACTB (4352341E) transcripts, were quantified by quantitative real time PCR using TaqMan Universal PCR Master Mix and Assays-onDemand Gene Expression probes (Applied Biosystems). Reactions were performed in 96-well plates with 25 μl volumes. Cycling conditions were: 2 min at 50°C, 95°C for 10 min, and followed by 40 cycles of PCR (15 s at 95°C and 1 min at 60°C). Products were detected with the ABI Prism7000 sequence detection system (Applied Biosystems).
The expression of each transcript in control and DMD fibroblasts, myoblasts and muscle was normalized to the expression of β-actin and determined as the ratio of the target transcript to the β-actin transcript calculated by 2 Group AT-hook 2) (Applied Biosystems) system was used as positive control in fibroblast miRNA inhibition experiments, while miR-1/ TWF1 (Applied Biosystems) system was used as positive control in myoblast miRNA mimic experiments. After miRNA inhibitor let-7c transfection, a significant increase in mRNA levels of HMGA2 was detected in fibroblasts; while after miRNA mimic miR-1 transfection, a significant decrease in TWF1 mRNA levels was detected in myoblasts, as expected (data not shown).
Quantification of soluble/extracellular collagen in cell cultures
Total soluble (non cross-linked) collagen was measured in supernatants from control and DMD fibroblasts and myoblasts, by a quantitative dye-binding method using the Sircol collagen assay (Biocolor, Belfast, N. Ireland), according to the manufacturer's instructions. Protein concentration in collected supernatants was determined using the DC Protein Assay Reagent (Bio-Rad Laboratories, Hercules, CA, USA) and used for normalization of soluble collagen.
PAI-1 secretion and plasmin activity
PAI-1 secretion in cell cultures was evaluated by ELISA (Life Technologies) following the manufacturer's instructions, before and after TGF-β1 treatment, and after miR-21 inhibition.
Plasmin activity was measured indirectly in control and DMD fibroblasts using the plasmin-specific chromogenic substrate D-Val-Leu-Lys p-nitroanilide dihydrochloride (Sigma Aldrich). Culture supernatants (35 μl) were incubated at 37°C in a 96-well plate with 25 μl 0.1 M Tris-HCl (pH 7.6) containing 2 mM EDTA and with 10 μl 1.5 mM chromogenic substrate. P-nitroanilide release over 120 min was monitored by measuring absorbance at 405 nm with a microplate reader (Victor Wallac 1420, Perkin Elmer, San Diego, CA, USA). Plasmin activity was normalized to cell number (determined by MTT assay, as described in [56] ) in each well.
Immunocytochemistry
After fixation in 4% paraformaldehyde for 30 min and permeabilization with 0.1% Triton-X 100 for 10 min, cells were incubated in PBS containing 1% BSA for 30 min at room temperature, and overnight at 4°C with one of the following antibodies: mouse monoclonal anti-PTEN (Sigma, 1:30 dilution), rabbit polyclonal anti-collagen I (Chemicon, Millipore, Billerica, MA, USA; 1:150 dilution), mouse monoclonal anticollagen VI (Chemicon; 1:150 dilution) and rabbit polyclonal anti-PAI-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100 dilution). The cells were then incubated in Alexa 488-conjugated goat anti-rabbit IgG (for collagen I) or in Alexa 488-conjugated goat anti-mouse IgG (for PTEN and collagen VI) (both diluted 1:2000, Life Technologies) for 2 h, followed by DAPI (Sigma) 1:30,000 for 10 min. Cells were examined under a Zeiss Axioplan fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany) and pictures were taken with the same exposure settings. Muscle cryosections were incubated for 90 min in anti-collagen I or anti-collagen VI primary antibody, followed by incubation in Alexa 488-conjugated goat anti-mouse or anti-rabbit IgG, 1:2000, for 2 h. Connective tissue extent was measured on collagen VI-and collagen Iimmunostained sections at × 20 magnification using the NIH Image software version 1.62 (http://rsb.info.nih.gov/nih-image/), as previously described [57] .
Western blot
Fibroblasts transfected with miR-21 inhibitor were washed with PBS and lysed in extraction buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% Nonidet-P, 1% Triton X-100) containing a protease inhibitor cocktail (Pierce Biotechnology, Rockford, IL, USA) for 30 min on ice. The lysate was centrifuged (18,000 g, 15 min, 4°C), the supernatant collected, and its protein concentration determined with DC Protein Assay Reagent (Bio-Rad). Aliquots containing 30 μg protein were solubilized in 2× Laemmli buffer (0.5 M Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 5% 2-mercaptoethanol, 1% bromophenol blue), boiled, separated by 4-10% SDS polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes (Schleicher and Schuell, Keene, NH, USA). Membranes were probed with anti-PTEN (mouse monoclonal, 1:500; Sigma), anti-Spry-1 (rabbit polyclonal, 1:250; Santa Cruz) anti-AKT (rabbit polyclonal, 1:300; Cell Signaling Technology, Boston, MA, USA), and anti-pAKT (mouse monoclonal, 1:300; Cell Signaling Technology).
Extracellularly secreted collagen I was detected in culture medium. Supernatant proteins were separated on 4-10% SDS-PAGE. In the absence of a reference standard (not available for extracellularly secreted proteins) all lanes were loaded with equal amounts (40 μg) of total protein. After separation biotin-conjugated secondary antibody was applied (1:2500; Jackson ImmunoResearch), followed by peroxidase-conjugated streptavidin (1:3000; Jackson ImmunoResearch), and detection with the ECL chemiluminescence reagent (Amersham Biosciences).
Animals and experiments on mdx mice
C57BL/10ScSn-Dmdmdx/J mice were from Jackson Laboratory (Bar Harbor, Maine, USA). Animal studies were approved by our review board, in accordance with the Italian Health Ministry guidelines. Animal care and use was in accordance with the Italian law and the EU directive 2010/63/EU. The animals were housed in our facility under 12 h light/12 h dark conditions with free access to food and water.
To knockdown miR-21 expression in three-month-old mdx mice (5 per group), antagomiR-21 (5′-CCATCGACTGCTGTT-3′) or scrambled (5′-ACGTCTATACGCCCA-3′) locked nucleic acid oligonucleotides (Exiqon A/S, Vedbaek, Denmark) were injected intraperitoneally (10 mg/kg in PBS) using a 26-gauge needle. Three injections were given (day 1, 48 h after first injection, and 15 days after first injection). Four weeks after first injection, the animals were sacrificed by cervical dislocation under anaesthesia; the diaphragm muscles were rapidly removed, frozen in isopentane pre-cooled in liquid nitrogen, and maintained in liquid nitrogen pending use. Haematoxylin and eosin (H&E), Gomori modified trichrome, acid phosphatase, and immunohistochemical stainings were performed on consecutive 6-8 μm-thick cryosections. Numbers of acid-phosphatase-positive cells from highly inflamed and mildly inflamed regions were counted on micrographs of acid phosphatase-stained sections, as described in Gibertini et al. [13] .
Muscle fibrosis was quantified on diaphragm preparations immunostained to reveal collagens I and VI together. To block non-specific binding, sections were preincubated (30 min) with 10% goat serum (Jackson ImmunoResearch) in PBS, followed by incubation (2 h) with both anticollagen I (Chemicon, 1:40) and anti-collagen VI (Santa Cruz, 1:100) polyclonals. Incubation (60 min) with Alexa 488-goat anti-rabbit IgG (1:2000, Life Technologies) followed. As control, sections were incubated either with rabbit non-immune serum, or isotype-specific nonimmune IgG (Dako), or the primary antibodies were omitted. The area of collagen immunostaining, as indicator of fibrosis, was determined at × 20 magnification as described [13] . Briefly, 4 randomly selected fields were photographed from each section and digitalized. Using the software, the photographs were inverted and a threshold was applied to obtain black and white images with areas positive for collagens in black and negative areas in white. Manual corrections were sometimes applied to eliminate non-muscle/non-fibrosis areas or to add areas not recognized by the software. The area positive for collagens was calculated as a percentage of the entire image, and the mean percentage for each group of animals calculated.
Quantitation of soluble collagens in mdx diaphragm
Acid-soluble collagen concentration was determined in mouse diaphragms by the Sircol Collagen Assay (Biocolor), according to the manufacturer's instructions. Briefly, tissue samples were incubated over-night at 4°C in 0.5 M acetic acid. 20 μl of samples' acid-soluble collagens and reference standard were added to 200 μl of the colorimetric reagent and gently mixed for 30 min, followed by centrifugation at 10,000 g for 10 min. To remove unbound dye a wash with ice-cold Acid-Salt Buffer wash was performed. The SR dye was released from the pellet with Alkali Reagent and colorimetric readings were taken in duplicate at 550 nm. The amount of soluble collagens was expressed as μg of collagens per mg of tissue.
Statistical methods
Results were expressed as means and standard deviations (±). Differences between DMD and control were assessed by the two-tailed Student's t-test or one-way ANOVA with post-hoc Dunnett's test, where appropriate. Differences in gene expression between cells treated and not treated with TGF-β1 were assessed using a mathematical model based on PCR efficiency described by Pfaffl [36] . P values ≤ 0.05 were considered significant. ELISA data were processed using a fourparameter logistic model (Readerfit programme; http://www. readerfit.com/). Each experiment, performed in duplicate or triplicate, used separate cultures obtained from three DMD patients and three controls.
Associations of miRNA (miR-21, miR-29a, miR-29c) expression levels with levels of collagen I and VI transcripts and proteins (considered markers of fibrosis, [61] ), and patient age (considered an indicator of disease progression [18] ), were assessed by Pearson's linear regression analysis.
Results
3.1. MiR-21 was increased and miR-29 decreased in DMD muscle; miR-21 was upregulated in DMD fibroblasts, and miR-21, miR-29a and miR-29c levels were downregulated in DMD myoblasts
In DMD muscles, levels of miR-21 (6.95 ± 6.40, p b 0.001) were significantly higher, and levels of miR-29a (0.29 ± 0.12, p b 0.001) and miR-29c (0.32 ± 0.15, p b 0.001) significantly lower than in control muscles (Fig. 1G) . Similarly, in MDC1A muscles, levels of miR-21 were significantly higher (3.06 ± 0.54, p b 0.001), and levels of miR-29a (0.10 ± 0.05, p b 0.001) and miR-29c (0.015 ± 0.007, p b 0.001) were significantly lower than in controls (not shown).
MiR-21 expression (R = 0.74, p b 0.05) ( In fibroblasts not treated with TGF-β1, miR-21 expression levels were significantly higher in DMD fibroblasts (1.86 ± 0.37; p b 0.05) than control fibroblasts (expressed as 1). No differences in miR-29a (0.95 ± 0.32, p = 0.94) or miR-29c (0.74 ± 0.18, p = 0.08) expression were found in DMD compared to control fibroblasts (Fig. 1H) .
After TGF-β1 treatment miR-21 expression was significantly higher (2.11 ± 0.08, p b 0.001), and miR-29a (0.59 ± 0.13, p b 0.05) and miR-29c (0.64 ± 0.06, p b 0.05) expression significantly lower, in DMD fibroblasts compared to similarly treated control fibroblasts (Fig. 1I ). There were no significant differences between treated and untreated control fibroblasts or between treated and untreated DMD fibroblasts.
As regards myoblasts not treated with TGF-β1, miR-21 (0.62 ± 0.23, p b 0.05), miR-29a (0.46 ± 0.09, p b 0.001) and miR-29c (0.48 ± 0.19, p b 0.05) levels were significantly lower in DMD myoblasts than in controls (expressed as 1) (Fig. 1J) .
After TGF-β1 treatment, mR-21 expression (1.1 ± 0.37, p = 0.67) and miR-29a (0.52 ± 0.33, p = 0.06) in DMD myoblasts were no longer significantly lower than in controls, while miR-29c levels (0.45 ± 0.21, p b 0.05) in DMD myoblasts remained significantly lower than those in controls (Fig. 1K ). There were no significant differences between treated and untreated control fibroblasts or between treated and untreated DMD myoblasts.
3.2. MiR-21 targets were downregulated in DMD fibroblasts; and miR-29 targets were upregulated in DMD myoblasts Search in the TargetScan or in microRNA database (www.targetscan. org and http://www.microrna.org), detected putative miR-21 or miR-29 binding sites in the untranslated regions of all the following target genes: PTEN and SPRY-1, both targets of miR-21; COL3A1, FBN1 and YY1, all targets of miR-29. These molecules have also been shown to be targets of miR-21 or miR-29, respectively, by 3′-UTR luciferase assay [28, 43, 44] .
In DMD fibroblasts not treated with TGF-β1, levels of PTEN (0. (Fig. 2A) . After TGF-β1 treatment, the levels of these transcripts in DMD fibroblasts did not change significantly compared to levels in untreated DMD fibroblasts (not shown).
In DMD myoblasts not treated with TGF-β1, COL1A1 (1.63 ± 0.34, p b 0.05) and COL6A1 (1.76 ± 0.35, p b 0.05) transcripts were significantly higher than those in untreated control myoblasts (Fig. 2B) . Levels of COL3A1, FBN1, and YY1, were also significantly higher in untreated DMD myoblasts than untreated controls (expressed as 1) (COL3A1: 2.09 ± 0.51, p b 0.05; FBN1: 1.68 ± 0.36, p b 0.05; YY1: 1.63 ± 0.15, p b 0.001) (Fig. 2B) . Following TGF-β1 treatment, levels of these transcripts in DMD myoblasts did not change significantly compared to those in untreated DMD myoblasts (not shown).
Transfection of miR-21 inhibitor and miR-29 mimic respectively lowered and increased miRNA levels
To further explore the effects of miRNAs in fibroblasts and myoblasts, the cells were transiently transfected with either miR-21 inhibitor or miR-29 mimics. Transfection efficiency was evaluated measuring miRNA levels by RT-PCR.
Forty-eight hours after transfection, miR-21 levels were significantly lower in inhibitor-transfected DMD fibroblasts than scrambledtransfected DMD fibroblasts: 0.38 ± 0.03 vs. 1.86 ± 0.37 (p b 0.05) (Fig. 3A) .
Forty-eight hours after transfection, miR-29a and miR-29c levels were significantly higher in mimic-transfected DMD myoblasts, than scrambled-transfected DMD myoblasts. Specifically, after miR-29a mimicking both miR-29a (13.18 ± 0.56 vs. 0.46 ± 0.11; p b 0.001) and miR29c (24.71 ± 6.21 vs. 0.46 ± 0.11; p b 0.05) were increased, and after miR-29c mimicking both miR-29a (6.74 ± 0.24 vs. 0.48 ± 0.18; p b 0.001) and miR-29c (37.48 ± 1.99 vs. 0.48 ± 0.18; p b 0.001) were increased. The effects of both miR-29a and miR-29c mimics together on transcription levels of miR-29a and miR-29c were also assessed. No significant differences in transcription levels of miR-29a and miR-29c after double transfection compared to single transfection were observed (miR-29a: 10.43 ± 1.8; miR-29c: 37.14 ± 6.00) (Fig. 3B) .
MiR-21 inhibitor and miR-29 mimic transfection modulate target transcripts
In DMD fibroblasts, decreasing miR-21 levels by miR-21 inhibitor transfection was sufficient to induce upregulation of miR-21 target transcripts and downregulation of fibrosis related transcripts compared to scrambled-transfected DMD fibroblasts. (Fig. 4A) .
In DMD myoblasts, increasing miR-29 levels by transfection with miR-29a and miR-29c mimics induced downregulation of miR-29 targets. Thus, after miR-29a mimicking, COL3A1 transcript levels were 0.52 ± 0.23 vs. 2.09 ± 0.51 in scrambled-transfected DMD myoblasts (Fig. 4B) .
COL1A1 and COL6A1 transcript levels were also evaluated in DMD myoblasts before and after miR-29 mimicking. In all conditions tested (miR-29a, miR-29c, miR-29a plus miR-29c), both COL1A1 and COL6A1 mRNA levels were significantly lower than in scrambled-transfected DMD myoblasts. Thus, after miR-29a mimic, COL1A1 was 0.27 ± 0. (Fig. 4C) .
MiR-21 inhibitor and miR-29 mimic transfection modulated protein expression
PTEN was not detected by immunocytochemistry in scrambledtransfected DMD fibroblasts in basal conditions, but was expressed in the cytosol after miR-21 inhibition. Both collagen I and collagen VI In all cases target transcript levels were normalized to β-actin expression levels and data are presented as means ± standard deviations (data from three duplicated experiments for three cell lines of each cell type).
immunostaining was clearly reduced in inhibitor-transfected compared to scrambled-transfected DMD fibroblasts (Fig. 5A) . Collagen I and collagen VI immunostaining was also clearly reduced in DMD myoblasts after miR-29a and miR-29c mimicking, compared to scrambledtransfected DMD myoblasts (Fig. 5B) .
To determine whether PTEN is post-transcriptionally inhibited by miR-21, PTEN protein expression was further assessed in DMD fibroblasts by Western blot. A marked increase in PTEN protein after DMD fibroblast transfection with miR-21 inhibitor was found compared to scrambled-transfected DMD fibroblasts, showing that PTEN is a direct target of miR-21 (Fig. 5C) . Since PTEN is a negative regulator of the Akt/PI3-kinase pathway, Akt/PI3K downstream signalling was also evaluated: it was found that phosphorylated-Akt (Ser473) was reduced after miR-21 silencing in DMD fibroblasts (Fig. 5C ). Akt/PI3K signalling has also been implicated in collagen production [24] , so collagen I expression in DMD fibroblast supernatants was evaluated. MiR-21 inhibition induced a decrease in collagen I expression compared to DMD scrambled-transfected fibroblasts (Fig. 5C ). Spry-1 expression was also increased in DMD fibroblasts after miR-21 inhibition (Fig. 5C ).
MiR-21 inhibitor and miR-29 mimic transfection modulated soluble collagen production
Under basal conditions, soluble collagen production was significantly greater in the culture medium of DMD fibroblasts than in medium of control fibroblasts (237.71 ± 12.88 μg/ml vs. 135.53 ± 1.49 μg/ml; p b 0.05). TGF-β1 treatment induced a further significant increase in soluble collagen production in DMD fibroblasts only (385.83 ± 38.47 μg/ml, p b 0.05). MiR-21 silencing induced a significant reduction in soluble collagen production both in DMD (35.94 ± 10.69 μg/ml; p b 0.001) and control fibroblasts (44.41 ± 19.25 μg/ml; p b 0.05) compared to medium from scrambled-transfected cells (Fig. 6A) .
Under basal conditions soluble collagen production was significantly higher in culture medium of DMD myoblasts than control myoblast medium (131.73 ± 18.91 μg/ml vs. 37.02 ± 0.92 μg/ml; p b 0.05). TGF-β1 treatment had no significant effects. Only transfection of control myoblasts with miR-29c mimic induced a significant reduction in soluble collagen production compared to scrambled-transfected control myoblasts (19.89 ± 4.66 μg/ml vs. 37.02 ± 0.92 μg/ml; p b 0.05). In DMD myoblasts, by contrast, significant reductions in collagen production occurred after miR-29a (55.63 ± 13.56 μg/ml; p b 0.05), miR-29c (67.46 ± 7.23 μg/ml, p b 0.05) and miR-29a plus miR-29c mimic transfection (48.77 ± 6.58 μg/ml; p b 0.05) compared to scrambledtransfected myoblasts (131.73 ± 40.12 μg/ml) (Fig. 6B) .
PAI-1/plasmin were downregulated by miR-21 inhibition in DMD fibroblasts
Transcript levels of PAI-1 were significantly higher in DMD fibroblasts (2.19 ± 0.12) than control fibroblasts (p b 0.001), and increased further after TGF-β1 treatment (2.42 ± 0.22, p b 0.001). No significant difference between basal DMD fibroblasts (not treated with TGF-β1) and TGF-β1-treated fibroblasts was observed. PAI-1 transcript levels were significantly lower in DMD fibroblasts after miR-21 silencing compared to control fibroblasts (0.34 ± 0.27 vs. 2.19 ± 0.12; p b 0.05; Fig. 7A ).
PAI-1 protein was expressed in a punctate pattern in the nucleus and cytoplasm of DMD fibroblasts in basal conditions; after miR-21 silencing positivity decreased in both compartments (Fig. 7B) .
PAI-1 production was significantly higher in basal conditions in DMD fibroblasts (965.08 ± 37.82 pg/ml) than control fibroblasts (261.53 ± 53.99 pg/ml; p b 0.05). TGF-β1 treatment induced a significant increase in PAI-1 production both in DMD (4638.11 ± 143 pg/ml; p b 0.05) and control (3602.75 ± 297 pg/ml; p b 0.05) fibroblasts, compared to untreated cells. MiR-21 silencing in DMD fibroblasts significantly reduced PAI-1 production (437.88 ± 132 pg/ml vs. 965.08 ± 37.82; p b 0.001) compared to DMD fibroblasts under basal conditions (Fig. 7C) .
The enzymatic activity of plasmin was significantly lower in DMD fibroblast culture medium than control fibroblast medium (3.37 ± 0.46 ng substrate/min vs. 10.29 ± 4.58; p b 0.05). Plasmin activity significantly increased in DMD fibroblast medium after miR-21 inhibition (7.47 ± 0.76 ng substrate/min; p b 0.001) compared to untransfected DMD fibroblasts (Fig. 7D) .
AntagomiR-21 treatment reduced muscle fibrosis in mdx mouse diaphragm
Histological evaluation of diaphragm muscle of mdx mice treated with antagomiR-21 showed that the morphology was better organized than scramble-treated diaphragms (Figs. 8A, B) . Numbers of acid phosphatase positive cells did not differ significantly between, respectively, highly or mildly inflamed regions of muscles from antagomiR-21-treated, and highly or mildly inflamed regions of muscles from scramble-treated mice (not shown). Assessment of miR-21 targets in diaphragm showed that PTEN (2.25 ± 0.81; p b 0.01) and SPRY-1 (1.61 ± 0.82; p b 0.05) transcript levels were significantly higher in antagomiR-21-treated compared to scramble-treated diaphragms (expressed as 1) (Fig. 8E) . Immunostaining of diaphragm showed that collagen I and collagen VI were present in the perimysium and endomysium and that areas of collagen I/collagen VI positivity (Figs. 8C,D) were significantly lower in antagomiR-21-treated (19.02 ± 2.71% area) than scramble-treated diaphragms (22.56 ± 4.41% area; p b 0.01) (Fig. 8F) .
Assessment of soluble collagens extracted from the diaphragm of treated and untreated animals revealed that collagens were significantly reduced in antagomiR-21-treated than scramble-treated diaphragms (41.42 ± 5.04 vs. 48.8 ± 4.86 μg/mg of tissue; p b 0.05) (Fig. 8G ).
Discussion
Our extensive investigations of miR-21 and miR-29 on DMD muscle and muscle-derived cells, show that miR-21 is upregulated in DMD muscles and fibroblasts and miR-29 is downregulated in DMD muscles and myoblasts, with corresponding profibrotic alterations in target transcript and protein expression. Our miRNA inhibition and mimicking experiments directly implicate miR-21 and miR-29 in fibrosis-related alterations of target transcript and protein expression, and in increased production of ECM proteins and other profibrotic molecules. Overall our data show that these miRNAs have fundamental but opposing roles in regulating fibrosis in skeletal muscle (Fig. 9 ).
MiR-21 upregulation and its implications
We found that miR-21 was upregulated in DMD muscle, and that levels correlated directly with COL1A1 and COL6A1 transcript levels (markers of fibrosis, [61] ) and also age (marker of disease progression [18] ).
MiR-21 upregulation in DMD muscle and fibroblasts, together with upregulation of collagen, downregulation of known miR-21 targets involved in fibrogenesis, and interaction with TGF-β1, all strongly implicate this miRNA as a major player in DMD fibrosis. We also found that miR-21 is upregulated in highly fibrotic muscle biopsies from MDC1A patients, implying that miR-21 is involved in muscle fibrosis in general.
These findings are fully consistent with recent data showing that miR-21 is upregulated in fibrosis of lung, heart, liver and kidney [6, 12, 23, 32] , while increased levels of miR-21 in fibroblasts have been found in several other conditions. Thus, Thum et al. [43] showed that miR-21 was weakly expressed in normal myocardium, but after infarction miR-21 levels increased in cardiac fibroblasts, in direct correlation with increased atrial collagen content and reduced SPRY-1 expression. Roy et al. [38] found increased miR-21 levels in murine cardiac fibroblasts during heart remodelling after induced myocardial infarction, and identified PTEN as a direct target of miR-21. In liver fibrosis, miR-21 is also upregulated and has been shown to activate stellate cells via PTEN/Akt signalling. Stellate cells are liver-specific and play fundamental roles in several biological and pathological processes including fibrogenesis [50] .
The results of our miR-21-silencing experiments in DMD fibroblasts provide further evidence of miR-21 involvement in DMD fibrosis, since silencing resulted in upregulation of PTEN and SPRY-1 indicating that their downregulation is due to miR-21.
PTEN is a key regulator of the cell cycle, cell motility and apoptosis [51] . During normal tissue repair, PTEN upregulation due to ECM contraction induces inhibition of the Akt/PI3-kinase pathway and triggers fibroblast apoptosis and termination of the repair process [31] . In fibrotic conditions, reduction of PTEN expression increases Akt/PI3-kinase signalling and hence fibroblast proliferation and viability, thereby favouring increased fibrosis [33] . In DMD fibroblasts we found that miR-21 upregulation was associated with reduced PTEN expression (transcript and protein) and Akt pathway activation (Western blot of phosphorylated Akt), while miR-21 silencing rescued PTEN and reduced Akt activation. We also found that miR-21 silencing reduced collagen I protein expression, probably in relation to reduced Akt activation. Lu et al. [24] demonstrated that in human lung fibroblasts the Akt/PI3K pathway is involved in collagen production and fibroblast proliferation, while more recently He et al. [17] demonstrated that PTEN overexpression in lung fibroblasts suppresses collagen I production by inhibiting the Akt/PI3K pathway. Bujor et al. [7] also found that activated Akt has profibrotic effects in dermal fibroblasts, promoting collagen synthesis and reducing MMP-1 activity.
As regards SPRY-1 transcripts, their expression is reduced in failing heart, resulting in increased levels of extracellular signal-regulated kinases (ERK), which contribute to fibroblast survival and to interstitial fibrosis [43] . So, reduced expression of this target for miR-21 appears to promote fibrosis and is also consistent with our previous finding that the ERK pathway is upregulated in the same cells [54] . We also found that miR-21 inhibition in DMD fibroblasts induced increased expression of SPRY-1 protein.
MiR-21 and TGF-β1
TGF-β1 has an established role in fibrosis. Increased levels of TGF-β1 in DMD muscle had been reported previously by our group and others [4, 15, 26, 57] . In the present study we found that treatment of fibroblasts with TGF-β1 resulted in increased miR-21 levels. This is interesting in light of previous studies [6, 53] showing that miR-21 downregulation inhibits TGF-β1-induced transdifferentiation of fibroblasts to myofibroblasts, while miR-21 upregulation promotes transdifferentiation. Myofibroblasts are principally responsible for increased collagen synthesis in DMD and other fibrotic conditions [29] .
The PAI-1/plasmin system
In view of our finding [54, 55] that muscle-derived fibroblasts from DMD patients are fibrogenic, we investigated the PAI-1/plasmin system in fibroblasts. This system, in addition to being a negative regulator of the proteolytic activity of plasmin, is also involved in fibrosis and the regulation of miR-21 biogenesis [3] . We found significantly upregulated PAI-1 transcript and protein levels in DMD fibroblasts -further increased by TGF-β1 treatment -with consequent significant reduction in plasmin activity, suggesting that PAI-1 is directly involved in altered ECM homeostasis in DMD. PAI-1 is also linked to miR-21, since we found that miR-21 inhibition in DMD fibroblasts caused a significant reduction in PAI-1 mRNA levels and a significant increase in plasmin activity.
MiR-21 downregulation as anti-fibrotic therapy
Our findings therefore suggest miR-21 inhibition as a possible approach to reducing fibrosis, since inhibition not only has an antifibrotic effect on known target transcripts, but also an antifibrotic regulatory action on the PAI-1/plasmin system. Previous data also indicate that miR-21 inhibition can reduce fibrosis. Thus in a mouse cardiac hypertrophy model, miR-21 silencing inhibited interstitial fibrosis [43] ; miR-21 antisense probes diminished the severity of induced lung fibrosis in mice and attenuated the pro-fibrogenic activity of TGF-β1 in fibroblasts [23] ; and antagomiR-21 injection prevented fibrosis in a mouse model of heart infarction [1] . Our experiments on mdx mice showed that antagomiR-21 treatment effectively reduced not only levels of target transcripts but also extent of fibrosis and soluble collagen production. These effects were evident only a month after treatment at lowest dose reported effective in the literature [14, 25, 35] . Thus miR-21 silencing shows promise as an anti-fibrosis therapy. Other miRNAs have been shown to be important modulators of the dystrophic phenotype. For example, Cordani et al. [8] recently showed that nitric oxide-induced upregulation of miR-27 was able to inhibit adipogenesis, which is an integral part of the fibrotic process.
MiR-29 downregulation and its implications
The miR-29 family comprises miR-29a, miR-29b and miR-29c that have similar sequences, expression patterns and functions [21] . MiR29s are known to suppress fibrosis by suppressing the expression of various ECM components [19] . Reduced miR-29 expression has been implicated in the development of fibrosis in liver, kidney, lung and heart [16] .
Our findings showing that miR-29a and miR-29c expression is reduced in DMD muscle biopsies and myoblasts (and also in highly fibrotic muscle biopsies from MDC1A patients), and that miR-29a and miR-29c mimicking in DMD myoblasts results in modulation of target transcripts involved in fibrosis [44] , suggest that miR-29 upregulation may be a useful mitigation strategy in advanced disease when myoblasts are producing greater quantities of ECM components (normally fibroblasts are the main producers of ECM components).
As well as acting as an anti-fibrogenic regulator, miR-29 also promotes myogenesis by directly inhibiting YY1, a negative regulator of muscle genes [46] . Thus, muscle regeneration inhibited by upregulation of YY1 was reversed by miR-29 upregulation [49] . Our findings that miR-29 downregulation and YY1 upregulation in DMD myoblasts in basal conditions were reversed after miR-29 mimicking, are in agreement with those of Wang et al. [49] .
Conclusions
Ardite et al. [3] showed that miR-21 is involved in DMD fibrosis, while Wang et al. [47] showed that miR-29 is involved in fibrosis in the mdx mouse. Our data amplify these findings by showing that miR-21 is upregulated in DMD muscles and fibroblasts and miR-29 is downregulated in DMD muscles and myoblasts, with corresponding profibrotic alterations in target transcript and protein expression. Importantly we also show that miR-21 inhibition and miR-29 mimicking in fibrogenic and myogenic cells from DMD patients directly implicate miR-21 and miR-29 in profibrotic alterations of target transcript and protein expression, as well as the increased production of several ECM proteins. Taken together these findings show that miR-21 and miR-29 have fundamental but opposing roles in regulating fibrosis in skeletal muscle.
Finally our studies on mdx mice indicate that miR-21 inhibition has promise as an agent for contrasting muscle fibrosis. In general miRNA modulators can be administered easily, have long duration of action (up to 6 weeks in mice), are well tolerated, modulate miRNAs in most organs [34] and have more selective actions than the various pleiotropic molecules proposed as anti-fibrotic agents so far [2, 45, 60] . Effective miRNA mimics have become available for whole animal use only very recently. Montgomery et al. [30] in their study have shown that miR-29 mimics decrease collagen expression and block and reverse bleomycin-induced pulmonary fibrosis. Our study suggests that a combination of miR-21 inhibition and miR-29 upregulation could be a more effective strategy for treating muscle fibrosis.
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